Nothing Special   »   [go: up one dir, main page]

BR112020018585A8 - Uso de mimeticos de restrição calórica para potencializar a quimioimunoterapia para o tratamento de câncer - Google Patents

Uso de mimeticos de restrição calórica para potencializar a quimioimunoterapia para o tratamento de câncer

Info

Publication number
BR112020018585A8
BR112020018585A8 BR112020018585A BR112020018585A BR112020018585A8 BR 112020018585 A8 BR112020018585 A8 BR 112020018585A8 BR 112020018585 A BR112020018585 A BR 112020018585A BR 112020018585 A BR112020018585 A BR 112020018585A BR 112020018585 A8 BR112020018585 A8 BR 112020018585A8
Authority
BR
Brazil
Prior art keywords
crms
cancer
chemoimmunotherapy
caloric restriction
enhance
Prior art date
Application number
BR112020018585A
Other languages
English (en)
Other versions
BR112020018585A2 (pt
Inventor
Kroemer Guido
Levesque Sarah
Pol Jonathan
Original Assignee
Inst Nat Sante Rech Med
Univ Paris
Univ Sorbonne
Assist Publique Hopitaux Paris Aphp
Univ Paris Saclay
Univ Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Paris, Univ Sorbonne, Assist Publique Hopitaux Paris Aphp, Univ Paris Saclay, Univ Paris Cite filed Critical Inst Nat Sante Rech Med
Publication of BR112020018585A2 publication Critical patent/BR112020018585A2/pt
Publication of BR112020018585A8 publication Critical patent/BR112020018585A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

USO DE MIMETICOS DE RESTRIÇÃO CALÓRICA PARA POTENCIALIZAR A QUIMIOIMUNOTERAPIA PARA O TRATAMENTO DE CÂNCER . Na maioria dos casos, a quimioterapia e a imunoterapia contra o câncer não produzem respostas duráveis e a regressão completa e permanente dos tumores estabelecidos é rara. Aqui, os inventores mostram que os chamados miméticos de restrição calórica (CRMs), que são compostos naturais ou sintéticos que mimetizam farmacologicamente os efeitos do jejum ou da restrição calórica, podem ser usados para aumentar a probabilidade de cura do câncer. A administração de vários CRMs quimicamente distintos (como hidroxicitrato, ácido lipoico e a espermidina poliamina natural) levou à regressão completa e à indução de respostas imunológicas de proteção anticancerígenas em modelos de camundongos. Este efeito foi alcançado quando CRMs foram combinados com quimioterapia e imunoterapia tendo como alvo as moléculas de ponto de verificação imunológico CTLA-4 e/ou PD-1. Portanto, a restrição calórica e os CRMs podem ser usados para sensibilizar os cânceres à quimioimunoterapia.
BR112020018585A 2018-03-12 2019-03-11 Uso de mimeticos de restrição calórica para potencializar a quimioimunoterapia para o tratamento de câncer BR112020018585A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18305257 2018-03-12
EP18305257.0 2018-03-12
EP18305359 2018-03-29
EP18305359.4 2018-03-29
PCT/EP2019/056041 WO2019175113A1 (en) 2018-03-12 2019-03-11 Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers

Publications (2)

Publication Number Publication Date
BR112020018585A2 BR112020018585A2 (pt) 2020-12-29
BR112020018585A8 true BR112020018585A8 (pt) 2022-12-06

Family

ID=66102028

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020018585A BR112020018585A8 (pt) 2018-03-12 2019-03-11 Uso de mimeticos de restrição calórica para potencializar a quimioimunoterapia para o tratamento de câncer

Country Status (11)

Country Link
US (1) US20210030703A1 (pt)
EP (1) EP3765085A1 (pt)
JP (1) JP2021517589A (pt)
KR (1) KR20210004966A (pt)
CN (1) CN112218658A (pt)
AU (1) AU2019236402A1 (pt)
BR (1) BR112020018585A8 (pt)
CA (1) CA3093742A1 (pt)
RU (1) RU2020133451A (pt)
SG (1) SG11202008696RA (pt)
WO (1) WO2019175113A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2021095599A1 (pt) * 2019-11-13 2021-05-20
IT202000007153A1 (it) * 2020-04-03 2021-10-03 Ifom Fondazione St Firc Di Oncologia Molecolare Apporto calorico ridotto e immunoterapia per il trattamento del cancro
CN114053230B (zh) * 2021-12-09 2023-01-24 苏州百迈生物医药有限公司 一种表柔比星复方制剂及其制备方法和应用
WO2022250070A1 (ja) * 2021-05-28 2022-12-01 日本化薬株式会社 ウベニメクスと免疫チェックポイント阻害剤の併用
EP4370105A1 (en) * 2021-07-15 2024-05-22 Ludwig Institute for Cancer Research Ltd Use of methanol and prodrugs thereof in therapy
CN115590187A (zh) * 2021-10-08 2023-01-13 南京纽邦生物科技有限公司（Cn） 通过施用二氢小檗碱模拟热量限制的生物学益处的方法和组合物
EP4197525A1 (en) * 2021-12-20 2023-06-21 Scandion Oncology A/S Combination of drugs for the treatment of cancer
CN115531555B (zh) * 2022-08-19 2024-02-09 上海市第一人民医院 一种甘露糖修饰的纳米颗粒在制备治疗骨肉瘤药物中的应用
CN115282147A (zh) * 2022-08-31 2022-11-04 深圳市宝安区人民医院 罗拉匹坦或/和罗拉匹坦衍生物在抗结核分枝杆菌药物中的应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
GB9209628D0 (en) 1992-05-05 1992-06-17 Smithkline Beecham Plc Compounds
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
CN1328571B (zh) 1998-12-23 2016-08-31 辉瑞大药厂 抗ctla-4的人单克隆抗体
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EP3214175A1 (en) 1999-08-24 2017-09-06 E. R. Squibb & Sons, L.L.C. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
ES2524694T3 (es) 2002-10-17 2014-12-11 Genmab A/S Anticuerpos monoclonales humanos contra CD20
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0229734D0 (en) 2002-12-23 2003-01-29 Qinetiq Ltd Grading oestrogen and progesterone receptors expression
US7521051B2 (en) 2002-12-23 2009-04-21 Medimmune Limited Methods of upmodulating adaptive immune response using anti-PD-1 antibodies
US7257268B2 (en) 2003-02-28 2007-08-14 Aperio Technologies, Inc. Systems and methods for image pattern recognition
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP1907424B1 (en) 2005-07-01 2015-07-29 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US8501763B2 (en) 2007-03-16 2013-08-06 The Scripps Research Institute Inhibitors of focal adhesion kinase
UA97834C2 (ru) 2007-04-18 2012-03-26 Пфайзер Продактс Инк. Производные сульфониламида для лечения анормального роста клеток
US8023714B2 (en) 2007-06-06 2011-09-20 Aperio Technologies, Inc. System and method for assessing image interpretability in anatomic pathology
EP2242773B1 (en) 2008-02-11 2017-06-14 Cure Tech Ltd. Monoclonal antibodies for tumor treatment
JP2011512413A (ja) 2008-02-19 2011-04-21 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｆａｋの阻害剤としてのアニリノピリジン
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
EA020807B1 (ru) 2008-06-17 2015-01-30 Астразенека Аб Соединения пиридина
AU2009288289B2 (en) 2008-08-25 2012-11-08 Amplimmune, Inc. PD-1 antagonists and methods of use thereof
MX2011002252A (es) 2008-08-25 2011-06-24 Amplimmune Inc Composiciones de antagonistas del pd-1 y metodos de uso.
WO2010033508A1 (en) 2008-09-16 2010-03-25 Historx, Inc. Reproducible quantification of biomarker expression
US20140155410A1 (en) 2008-10-27 2014-06-05 Glaxosmithkline Llc Pyrazolylaminopyridines as inhibitors of fak
JO3067B1 (ar) 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
WO2010056919A2 (en) * 2008-11-12 2010-05-20 Kyphia Pharmaceuticals, Inc. Eflornithine prodrugs, conjugates and salts, and methods of use thereof
KR20200047793A (ko) 2008-12-09 2020-05-07 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
WO2010117057A1 (ja) 2009-04-10 2010-10-14 協和発酵キリン株式会社 抗tim-3抗体を用いた血液腫瘍治療法
US8289808B2 (en) 2009-04-16 2012-10-16 Chevron U.S.A., Inc. System and method to estimate compressional to shear velocity (VP/VS) ratio in a region remote from a borehole
US20110111435A1 (en) 2009-11-06 2011-05-12 SlidePath Limited Detecting Cell Surface Markers
PL3279215T3 (pl) 2009-11-24 2020-06-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
WO2011155607A1 (ja) 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体
WO2012101081A1 (en) 2011-01-25 2012-08-02 Shell Internationale Research Maatschappij B.V. Gasification reactor
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
MX2015011374A (es) 2013-03-15 2016-01-15 Squibb Bristol Myers Co Inhibidores de indolamina 2,3-dioxigenasa (ido).
CA2922607C (en) 2013-09-06 2022-08-30 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
CA2922655A1 (en) 2013-09-06 2015-03-12 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
EP3052133A2 (en) * 2013-10-03 2016-08-10 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof
MX2018000288A (es) * 2015-06-29 2018-11-09 Verastem Inc Composiciones terapeuticas, combinaciones y metodos de uso.

Also Published As

Publication number Publication date
AU2019236402A1 (en) 2020-10-01
WO2019175113A1 (en) 2019-09-19
CN112218658A (zh) 2021-01-12
JP2021517589A (ja) 2021-07-26
US20210030703A1 (en) 2021-02-04
BR112020018585A2 (pt) 2020-12-29
EP3765085A1 (en) 2021-01-20
KR20210004966A (ko) 2021-01-13
RU2020133451A (ru) 2022-04-12
SG11202008696RA (en) 2020-10-29
CA3093742A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
BR112020018585A8 (pt) Uso de mimeticos de restrição calórica para potencializar a quimioimunoterapia para o tratamento de câncer
BR112022008535A2 (pt) Composto, composição farmacêutica, métodos para tratar câncer e um distúrbio relativo à proteína ras
CY1123177T1 (el) Ρυθμιστης υποδοχεα ανδρογονου και χρησεις αυτου σε συνδυασμο με οξεικη αμπιρατερονη και πρεδνιζονη για τη θεραπεια καρκινου του προστατη
CY1123369T1 (el) Συνθεσεις και μεθοδοι για τη ρυθμιση της εκφρασης της απολιποπρωτεϊνης (α)
CY1120363T1 (el) Συζευγμα αντισωματος-φαρμακου
CY1124071T1 (el) Συζευγμα αντισωματος anti-her3 φapmakoy
CY1121925T1 (el) Συνδυαστικη θεραπεια με ενα ενζυμο που αποδομει την υαλουρονανη και εναν αναστολεα σημειων ανοσολογικου ελεγχου
CO2019013020A2 (es) Anticuerpo anti-cdh6 y conjugado farmaco-anticuerpo anticdh6
BR112018076525A2 (pt) membros de ligação a lag-3
BR112019000071A2 (pt) conjugados adjuvantes de anticorpo
CL2018002787A1 (es) Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos.
BR112015032690A8 (pt) uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir crescimento tumoral e metástases
BR112019005305A2 (pt) compostos espirocíclicos
BR112018069483A2 (pt) pró-fármacos de medicamentos citotóxicos contendo grupos enzimaticamente cliváveis.
BR112017005453A8 (pt) aminopiridiloxipirazol, seus usos, e composição farmacêutica.
BR112016028835A2 (pt) derivados de auristatina e conjugados dos mesmos
BR112016000489A8 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
BR112016007622A2 (pt) composto, composição farmacêutica, conjugado de ligante-droga, e, método para tratar câncer
BR112021022514A2 (pt) Conjugados de anticorpo e fármaco
MX366503B (es) Derivados de amatoxina.
BR112023006364A2 (pt) Terapia de combinação de imuno-oncologia com conjugados de il-2 e pembrolizumabe
MX2020004836A (es) Agentes anticancerígenos.
BR112019024719A2 (pt) Composições e métodos para resposta imunológica antitumor aprimorada
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112015026238A2 (pt) tratamento de câncer com dihidropirazino-pirazinas

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25G Requested change of headquarter approved

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; UNIVERSITE DE PARIS (FR) ; SORBONNE UNIVERSITE (FR) ; ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP) (FR) ; UNIVERSITE PARIS-SACLAY (FR)

B25D Requested change of name of applicant approved

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; SORBONNE UNIVERSITE (FR) ; ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP) (FR) ; UNIVERSITE PARIS-SACLAY (FR) ; UNIVERSITE PARIS CITE (FR)